Status and phase
Conditions
Treatments
About
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Subprotocol B
Inclusion:
Exclusion:
Primary purpose
Allocation
Interventional model
Masking
188 participants in 2 patient groups
There are currently no registered sites for this trial.
Central trial contact
Amgen Call Center
Start date
May 29, 2024 • 10 months ago
Today
Mar 29, 2025
End date
Feb 26, 2027 • in 1 year and 10 months
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal